| Size & multiples | |||
| Market Cap | — | Enterprise Value | — |
| P/E (TTM) | — | PEG (trailing) | — |
| P/S | — | P/FCF | — |
| EV/EBITDA | — | EV/EBIT | — |
| EV/Sales | — | EV/FCF | — |
| FCF Yield | — | Buyback Yield | — |
| Owner Earnings (TTM) | ₹56.54B | Owner Earnings Yield | — |
| Shareholder Yield | — | ||
| Cost of capital & EVAmethodology → | |||
| Beta (5y monthly) | 0.28 | Risk-free (assumed) | 4.00% |
| Equity risk premium (assumed) | 5.00% | Cost of Equity | 5.39% |
| After-tax Cost of Debt | 4.59% | Synthetic credit rating | AAA |
| Cost of Debt · embedded (pre-tax) | 6.16% | Cost of Debt · marginal (synthetic) | 4.40% |
| WACC | — | ROIC | 19.73% |
| EVA Spread (ROIC−WACC) | — | EVA | — |
FCF sits 67% below owner earnings — spending above maintenance (growth capex) or absorbing working capital, so FCF understates the steady-state cash the business throws off.
Synthetic rating = ICR-based credit-quality read (Damodaran), not an agency rating.
Flows latest annual · EPS TTM ₹67.78 · revenue TTM ₹325.54B · FCF TTM ₹18.92B (in INR)
Output of a disclosed model whose assumptions may be wrong — research information, not investment advice. See the Disclaimer.
Compared against all 1054 Health Care names we cover — one sector-wide pool, so the median skews toward smaller (often unprofitable) companies. Try the Size band for a cap-matched read.
| Metric | This (FY) | Peer median | IQR (25–75) | %ile |
|---|---|---|---|---|
| Net Margin | 17.4% | -21.2% | -325.3%–7.2% | 87 ↑strong |
| Operating Margin | 22.1% | -34.5% | -552.0%–8.0% | 92 ↑strong |
| ROE | 18.4% | -36.8% | -92.5%–4.5% | 88 ↑strong |
